Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.

Expert review of gastroenterology & hepatology - 1 Jan 2018

Hubbard Hope, Lawitz Eric

Abstract excerpt

INTRODUCTION: Glecaprevir (formerly ABT-493, pangenotypic NS3/4A protease inhibitor) and pibrentasvir (formerly ABT-530, pangenotypic NS5A inhibitor) are second generation direct acting antivirals (DAA) for the treatment of chronic Hepatitis C (HCV). It is a fixed dose ribavirin (RBV)-free regimen with activity against genotypes (GT) 1-6. In vitro the two antivirals have synergistic activity with a high barrier...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Benzimidazoles
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase III as Topic

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Pyrrolidines

Share to Quinoxalines

Source

Identifiers

PMID: 29187007
DOI: 10.1080/17474124.2018.1411802

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glecaprevir + pibrentasvir (ABT493 + ABT-530) for the treatment of Hepatitis C.PMID 29187007Read ↗

Glecaprevir/Pibrentasvir: First Global Approval.Semantic proximity Read ↗

Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy.Semantic proximity Read ↗

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.Semantic proximity Read ↗

Safety and efficacy of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection genotype 1–6 and chronic kidney disease: an integrated analysisSemantic proximity Read ↗

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.Semantic proximity Read ↗

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies.Semantic proximity Read ↗

Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.Semantic proximity Read ↗

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.Semantic proximity Read ↗

Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.Semantic proximity Read ↗

Recent Information on Pan-Genotypic Direct-Acting Antiviral Agents for HCV in Chronic Kidney Disease.Semantic proximity Read ↗

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver DiseaseSemantic proximity Read ↗

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.